CD4-CART

CD4-CART refers to a subtype of chimeric antigen receptor (CAR) T cell therapy in which the engineered cells are derived from the CD4+ subset of T lymphocytes. These cells are genetically modified to express a synthetic receptor (CAR) that targets specific antigens on tumor cells, enabling them to recognize and kill cancer cells independently of major histocompatibility complex (MHC) presentation. Unlike conventional CAR-T products that use mixed or unselected T cell populations, CD4-CART specifically utilizes purified or enriched CD4+ helper T cells. Studies have shown that these cells can mediate potent antitumor responses and may exhibit superior proliferation and sustained effector function compared to their CD8+ counterparts[1][3][5]. The mechanism involves direct cytotoxicity against tumor targets as well as orchestration of broader immune responses through cytokine secretion and support for other immune effectors[2][5]. However, excessive activation can contribute to inflammatory toxicities such as cytokine release syndrome (CRS)[1]. The approach is being explored both alone and in defined ratios with other subsets (e.g., 1:1 with CD8+) for hematologic malignancies like B-cell acute lymphoblastic leukemia and solid tumors such as glioblastoma[1][3][5].

Other names

CD4 CAR-TCD-4 CAR-TCD 4 CAR-TCD4+ CAR T cellCD4 chimeric antigen receptor T cellCD-4 chimeric antigen receptor T cellCD 4 chimeric antigen receptor T cell